TABLE III. Association between interleukin-28B genotype and three-level treatment outcome with multivariate logistic regression adjusted for age, gender, viral load and stage of liver fibrosis.
| Treatment
response |
Overall
n (%) |
CC
n (%) |
CT
n (%) |
TT
n (%) |
CC vs. CT
p |
CC vs. TT
p |
CT vs. TT
p |
|---|---|---|---|---|---|---|---|
| cEVR - week 12 | 158/269 (59) | 32/38 (84) | 76/132 (58) | 58/99 (59) | 0.002 | 0.005 | 0.894 |
| pEVR - week 12 | 58/269 (21) | 5/38 (13) | 30/132 (23) | 25/99 (25) | 0.257 | 0.167 | 0.755 |
| EOTR - week 48 | 175/270 (65) | 36/39 (92) | 83/130 (64) | 64/101 (63) | 0.001 | 0.001 | 1.000 |
| Relapse | 64/178 (35) | 6/35 (17) | 28/82 (34) | 30/61 (49) | 0.077 | 0.002 | 0.086 |
| SVR - week 72 | 114/263 (43) | 29/38 (76) | 54/128 (42) | 31/97 (32) | < 0.001 | < 0.001 | 0.128 |
CI: confidence interval; NVR: null virological response; OR: odds ratio; SVR: sustained virological response.